NCT06935409 2026-04-09
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
Hansoh BioMedical R&D Company
Phase 3 Active not recruiting
Hansoh BioMedical R&D Company
Boehringer Ingelheim
ImmunityBio, Inc.
Memorial Sloan Kettering Cancer Center